143 related articles for article (PubMed ID: 2876653)
1. Benefits and limitations of neuroleptics--and other forms of treatment--in schizophrenia.
Marder SR; May PR
Am J Psychother; 1986 Jul; 40(3):357-69. PubMed ID: 2876653
[TBL] [Abstract][Full Text] [Related]
2. [Never treated schizophrenic patients have no abnormal movements such as tardive dyskinesia].
Chorfi M; Moussaoui D
Encephale; 1985; 11(6):263-5. PubMed ID: 2869939
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic treatment of schizophrenia.
Levinson DF
Clin Ther; 1991; 13(3):326-52. PubMed ID: 1683269
[TBL] [Abstract][Full Text] [Related]
4. Prevention and management of tardive dyskinesia.
Jeste DV; Wyatt RJ
J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):14-8. PubMed ID: 2858473
[TBL] [Abstract][Full Text] [Related]
5. Minimization and overreaction to tardive dyskinesia.
Munetz MR; Schulz SC
Schizophr Bull; 1986; 12(2):168-72. PubMed ID: 2872721
[TBL] [Abstract][Full Text] [Related]
6. Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics.
Chouinard G; Jones BD
Am J Psychiatry; 1980 Jan; 137(1):16-21. PubMed ID: 6101522
[TBL] [Abstract][Full Text] [Related]
7. Depot neuroleptics: side effects and safety.
Marder SR
J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):24S-29S. PubMed ID: 2870089
[TBL] [Abstract][Full Text] [Related]
8. Clonidine treatment of schizophrenia. Double-blind comparison to placebo and neuroleptic drugs.
Freedman R; Kirch D; Bell J; Adler LE; Pecevich M; Pachtman E; Denver P
Acta Psychiatr Scand; 1982 Jan; 65(1):35-45. PubMed ID: 6138923
[TBL] [Abstract][Full Text] [Related]
9. Clinical use of the antipsychotics.
Kessler KA; Waletzky JP
Am J Psychiatry; 1981 Feb; 138(2):202-9. PubMed ID: 6109455
[TBL] [Abstract][Full Text] [Related]
10. Clinical forms of severe tardive dyskinesia.
Gardos G; Cole JO; Salomon M; Schniebolk S
Am J Psychiatry; 1987 Jul; 144(7):895-902. PubMed ID: 2886062
[TBL] [Abstract][Full Text] [Related]
11. Absence of neuroleptic-induced parkinsonism in psychotic patients receiving adjunctive electroconvulsive therapy.
Mukherjee S; Debsikdar V
Convuls Ther; 1994 Mar; 10(1):53-8. PubMed ID: 7914462
[TBL] [Abstract][Full Text] [Related]
12. Neuroleptic dosing and neuroleptic plasma levels in schizophrenia: determining the optimal regimen.
Shriqui CL
Can J Psychiatry; 1995 Sep; 40(7 Suppl 2):S38-48. PubMed ID: 8564916
[TBL] [Abstract][Full Text] [Related]
13. Drug treatment of schizophrenia. Overview of recent research.
Marder SR; Wirshing WC; Van Putten T
Schizophr Res; 1991; 4(2):81-90. PubMed ID: 1674883
[TBL] [Abstract][Full Text] [Related]
14. Preventing neuroleptic-induced tardive dyskinesia in adults and children.
Lam RW; Jeste SD; Jeste DV
Encephale; 1988 Sep; 14 Spec No():251-5. PubMed ID: 2905652
[TBL] [Abstract][Full Text] [Related]
15. The routine use of atypical antipsychotic agents: maintenance treatment.
Kinon BJ
J Clin Psychiatry; 1998; 59 Suppl 19():18-22. PubMed ID: 9847048
[TBL] [Abstract][Full Text] [Related]
16. Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia.
Sirota P; Mosheva T; Shabtay H; Giladi N; Korczyn AD
Am J Psychiatry; 2000 Feb; 157(2):287-9. PubMed ID: 10671405
[TBL] [Abstract][Full Text] [Related]
17. Composition and effects of commonly used neuroleptics.
Culshaw F
Nurs Times; 1994 Sep 21-27; 90(38):38-40. PubMed ID: 7971331
[TBL] [Abstract][Full Text] [Related]
18. Neuroleptic drugs: how to reduce the risk of tardive dyskinesia.
DeVeaugh-Geiss J
Geriatrics; 1979 Jul; 34(7):59-61, 66. PubMed ID: 36330
[TBL] [Abstract][Full Text] [Related]
19. Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia.
Casey DE
Psychiatr Clin North Am; 1993 Sep; 16(3):589-610. PubMed ID: 8105453
[TBL] [Abstract][Full Text] [Related]
20. The present status of tardive dyskinesia and akathisia in the treatment of schizophrenia.
Barnes TR
Psychiatr Dev; 1987; 5(4):301-19. PubMed ID: 2895467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
